📊 ASBPW Key Takeaways
Is Aspire Biopharma Holdings, Inc. (ASBPW) a Good Investment?
Aspire Biopharma is in severe financial distress with negative stockholders' equity of -$11.5M, indicating liabilities exceed assets and the company is technically insolvent. Operating losses of -$17.5M on minimal revenue of $1.9K demonstrate the company is pre-revenue with unsustainable cash burn of -$4.0M annually, consuming its limited cash reserves of $1.9M within months at current burn rates.
Aspire Biopharma's fundamentals are extremely weak: revenue is immaterial, operating losses are massive relative to scale, and free cash flow is deeply negative. The balance sheet is distressed, with negative stockholders' equity and a very weak current ratio, which raises substantial going-concern and dilution or financing risk unless the company can rapidly improve commercialization and funding access.
Aspire Biopharma Holdings, Inc. Key Strengths (ASBPW)
- Gross margin of 45.5% on limited product sales suggests potential unit economics if revenue scales
- Maintains $1.9M in cash providing short-term runway
- Healthcare/biotech sector has potential for significant upside if clinical/regulatory milestones achieved
- Positive gross profit indicates the product economics are not inherently negative at the unit level
- Cash of about $1.95M provides some near-term operating flexibility
- Asset-light balance sheet may allow management to pivot quickly if commercialization improves
ASBPW Stock Risks: Aspire Biopharma Holdings, Inc. Investment Risks
- Negative stockholders' equity of -$11.5M indicates technical insolvency and high bankruptcy risk
- Current ratio of 0.17x shows severe liquidity crisis with liabilities 5.8x current assets
- Operating cash flow of -$4.0M annual burn rate with only $1.9M cash means 5-6 months of runway remaining
- Negligible revenue of $1.9K indicates company has not achieved commercial traction
- Operating margin of -901,693% reflects massive losses relative to minimal sales base
- No insider purchases in 90 days suggests lack of confidence from management
- Revenue base is negligible relative to the cost structure, making current losses unsustainable
- Negative stockholders' equity and a 0.17x current ratio signal severe financial stress
- Operating cash burn of about $4.00M materially pressures liquidity and increases financing risk
Key Metrics to Watch
- Cash position and monthly burn rate - critical for survival timeline
- Revenue growth and path to positive unit economics - essential for viability
- Financing activity and debt restructuring announcements - likely necessity for continuation
- Clinical trial progress and regulatory milestones - only potential value driver
- Stockholders' equity trajectory - key indicator of solvency status
- Quarterly operating cash burn versus cash balance
- Revenue growth and gross profit scaling
Aspire Biopharma Holdings, Inc. (ASBPW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ASBPW Profit Margin, ROE & Profitability Analysis
ASBPW vs Healthcare Sector: How Aspire Biopharma Holdings, Inc. Compares
How Aspire Biopharma Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aspire Biopharma Holdings, Inc. Stock Overvalued? ASBPW Valuation Analysis 2026
Based on fundamental analysis, Aspire Biopharma Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aspire Biopharma Holdings, Inc. Balance Sheet: ASBPW Debt, Cash & Liquidity
ASBPW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aspire Biopharma Holdings, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.90 indicates the company is currently unprofitable.
ASBPW Revenue Growth, EPS Growth & YoY Performance
ASBPW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $28.4K | -$3.2M | $-20.57 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Aspire Biopharma Holdings, Inc. Dividends, Buybacks & Capital Allocation
ASBPW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aspire Biopharma Holdings, Inc. (CIK: 0001847345)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ASBPW
What is the AI rating for ASBPW?
Aspire Biopharma Holdings, Inc. (ASBPW) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 95% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ASBPW's key strengths?
Claude: Gross margin of 45.5% on limited product sales suggests potential unit economics if revenue scales. Maintains $1.9M in cash providing short-term runway. ChatGPT: Positive gross profit indicates the product economics are not inherently negative at the unit level. Cash of about $1.95M provides some near-term operating flexibility.
What are the risks of investing in ASBPW?
Claude: Negative stockholders' equity of -$11.5M indicates technical insolvency and high bankruptcy risk. Current ratio of 0.17x shows severe liquidity crisis with liabilities 5.8x current assets. ChatGPT: Revenue base is negligible relative to the cost structure, making current losses unsustainable. Negative stockholders' equity and a 0.17x current ratio signal severe financial stress.
What is ASBPW's revenue and growth?
Aspire Biopharma Holdings, Inc. reported revenue of $1.9K.
Does ASBPW pay dividends?
Aspire Biopharma Holdings, Inc. does not currently pay dividends.
Where can I find ASBPW SEC filings?
Official SEC filings for Aspire Biopharma Holdings, Inc. (CIK: 0001847345) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ASBPW's EPS?
Aspire Biopharma Holdings, Inc. has a diluted EPS of $-0.43.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ASBPW's fundamental grade?
Based on our AI fundamental analysis in June 2026, Aspire Biopharma Holdings, Inc. has a D grade with 95% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ASBPW stock overvalued or undervalued?
Valuation metrics for ASBPW: ROE of N/A (sector avg: 15%), net margin of -1,018,707.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ASBPW's AI grade for 2026?
Our dual AI analysis gives Aspire Biopharma Holdings, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ASBPW's free cash flow?
Aspire Biopharma Holdings, Inc.'s operating cash flow is $-4.0M, with capital expenditures of N/A. FCF margin is -205,855.1%.
How does ASBPW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,018,707.6% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.17 (avg: 2).